Piasky for Paroxysmal nocturnal hemoglobinuria
Quick answer: Piasky is used for Paroxysmal nocturnal hemoglobinuria as part of a complement c5 inhibitor (monoclonal antibody) treatment regimen. Crovalimab is a humanized monoclonal antibody that binds complement C5, preventing its cleavage and inhibiting terminal complement-mediated hemolysis The specific dosing for Paroxysmal nocturnal hemoglobinuria is determined by your prescriber based on individual factors.
Why is Piasky used for Paroxysmal nocturnal hemoglobinuria?
Piasky belongs to the Complement C5 inhibitor (monoclonal antibody) class. Crovalimab is a humanized monoclonal antibody that binds complement C5, preventing its cleavage and inhibiting terminal complement-mediated hemolysis This action makes it useful for treating or managing Paroxysmal nocturnal hemoglobinuria in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Piasky is the right choice for a specific patient depends on the type and severity of Paroxysmal nocturnal hemoglobinuria, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Paroxysmal nocturnal hemoglobinuria
Common adult dosing range: Weight-based loading then 680-1020 mg SC every 4 weeks. The actual dose for Paroxysmal nocturnal hemoglobinuria depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Piasky medicine page.
What to expect
Piasky treatment for Paroxysmal nocturnal hemoglobinuria typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Paroxysmal nocturnal hemoglobinuria
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Piasky is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Complement C5 inhibitor (monoclonal antibody) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Piasky
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Piasky full prescribing information · All Complement C5 inhibitor (monoclonal antibody) alternatives
Frequently asked questions
How effective is Piasky for Paroxysmal nocturnal hemoglobinuria?
Effectiveness varies by individual response, dose, and severity. Piasky is one of several treatment options for Paroxysmal nocturnal hemoglobinuria, supported by clinical evidence within the complement c5 inhibitor (monoclonal antibody) class. Discuss expected response with your prescriber.
How long do I need to take Piasky for Paroxysmal nocturnal hemoglobinuria?
Treatment duration depends on the nature of Paroxysmal nocturnal hemoglobinuria — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Piasky when used for Paroxysmal nocturnal hemoglobinuria?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Piasky for Paroxysmal nocturnal hemoglobinuria?
Yes. Multiple medicines and non-drug options exist for Paroxysmal nocturnal hemoglobinuria. Alternatives within the complement c5 inhibitor (monoclonal antibody) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.